[The clinico-immunological efficacy of the likopid treatment of chronic bronchitis patients].
OBJECTIVE
Elucidation of likopid effect on clinical and immunological pictures in patients with chronic bronchitis (CB).


METHODS
A trial of 52 CB patients in remission and exacerbation. 2 schemes of likopid treatment were used: 1 mg/day for 10 days (a course dose 10 mg); 10 mg/day for 6 days (a course dose 60 mg). Clinical and laboratory parameters, systemic immunity (measurement of lymphocyte subpopulations, levels of serum IgA, IgM and IgG, functional activity of peripheral blood phagocytes).


RESULTS
The 10 mg and 60 mg courses of likopid produced prolongation of remission to 5-6 months in 66% of CB patients in exacerbation and in 80% of patients in remission, respectively. 10 mg of likopid in exacerbation and 60 mg in remission promoted normalization of functional activity of blood phagocytes.


CONCLUSIONS
Likopid administration for CB in a 10 mg course dose in exacerbation and 60 mg course in remission prolongs CB remission to 5-6 months and promoted normalization of phagocytic functional activity.
Borisova
A M
AM
Setdikova
N Kh
NKh
Pinegin
B V
BV
Kulakov
A V
AV
Golubeva
N M
NM
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000188:drug therapy* / Q000276:immunology*; D002908:Chronic Disease; D006801:Humans; D007136:Immunoglobulins / Q000097:blood / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D008875:Middle Aged; D010586:Phagocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors
D000276:Adjuvants, Immunologic; D007136:Immunoglobulins; C089161:glikopin; D000119:Acetylmuramyl-Alanyl-Isoglutamine
Kliniko-immunologicheskaia éffektivnost' lecheniia likopidom bol'nykh khronicheskim bronkhitom.